New UAB Treatment Dispels Depression with Magnetism
By Bob Shepard
UAB is the first medical provider in Alabama to offer repetitive Transcranial Magnetic Stimulation treatments to patients suffering from depression. To learn more about this new form of therapy, click here.
Julia Rogers has battled depression for two decades. It has caused serious issues in her life, both personally and professionally. She tried medications—lots of them—with no real effect. Most days, she had to struggle just to function at all.
Depression is a difficult illness to treat because no single therapy works every time in every patient. Psychiatrists now have very good medications to offer, but many patients still find little relief. Psychotherapy and electroconvulsive therapy (ECT) are also successful for some patients, but they do little for others.
That’s why UAB psychiatrist Bates Redwine, M.D., is so excited about the university’s new repetitive Transcranial Magnetic Stimulation, or rTMS, device. This non-invasive treatment delivers a series of highly focused, MRI-strength magnetic pulses to a particular area of the brain linked to depression—the left dorsolateral prefrontal cortex. The Food and Drug Administration approved rTMS therapy within the past two years, and UAB’s device is the only one in Alabama.
“The left dorsolateral prefrontal cortex is known to have decreased activity in depressed patients,” says Redwine. “rTMS seems to ‘wake up’ the neurons, stimulating them to fire and become more active.”
The Pitfalls and Promise of Home Genetic Tests
By Tara Hulen
If Walgreens had its way, crystal balls would now be for sale alongside the candy bars and cough medicine at the drugstore chain’s stores. In May, Walgreens announced that it would start selling home genetic testing kits for as little as $20, becoming the first physical store to offer the tests—although they are widely available online. But the Food and Drug Administration (FDA), responding soon after the announcement, notified testing companies that they should have sought premarket approval, and Walgreens canceled the launch.
Although the FDA’s actions have led to calls for regulation of these direct-to-consumer tests, at the moment anybody wanting one won’t have much trouble finding them online from companies such as 23andMe. It’s a fairly simple process: Customers order a kit, mail in some saliva, and then receive a report with as much detail as they are willing to pay for. Options include ancestry tests, health screenings on several levels, and pre-pregnancy screening—which is a large market, says UAB Genetic Counseling Program Director R. Lynn Holt, M.S., CGC. The reports cover possible risks for various diseases, pharmacogenetics (a person’s sensitivity to prescription drugs such as blood thinners), or carrier status for diseases such as cystic fibrosis or Tay-Sachs, which can be passed on to children.
The prospect offered by these tests is intriguing—the thrill of looking back into the past or catching a glimpse of the future—but Holt says geneticists and genetic counselors have several concerns.
UAB Travel Medicine Expert Joins Global Health Panel
By Troy Goodman
David Freedman is a new member of the Roster of Experts for the World Health Organization International Health Regulations.
Disease knows no boundaries, and neither does David O. Freedman, M.D. At any time, the director of UAB’s Travelers’ Health Clinic could get a phone call summoning him to Europe to help stop a global epidemic.
Freedman isn’t a superhero. He’s an expert in travel medicine—and a new member of the Roster of Experts for the World Health Organization (WHO) International Health Regulations (IHR). A comprehensive set of rules and procedures endorsed by the 193 WHO member states, the IHR is designed to limit the worldwide spread of diseases and other public-health threats while minimizing disruption to travel, trade, and economies. “The emergence of H1N1 influenza in 2009 and SARS in 2003 demonstrates how interconnected the world has become and how rapidly a new disease can spread,” Freedman says.